![Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? - Pilz - Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? - Pilz -](https://cdn.amegroups.cn/journals/pbpc/files/journals/5/articles/287/public/287-PB4-R1.png/w300)
Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? - Pilz -
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma | Haematologica
![Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley](https://acsjournals.onlinelibrary.wiley.com/cms/asset/7ec0391a-b577-4b44-aac8-535a76de8de5/cncr30934-fig-0001-m.jpg)
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g003.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Survival curves. Progression-free survival (a) and overall survival (b)... | Download Scientific Diagram Survival curves. Progression-free survival (a) and overall survival (b)... | Download Scientific Diagram](https://www.researchgate.net/publication/337271695/figure/fig1/AS:825317845397504@1573782516286/Survival-curves-Progression-free-survival-a-and-overall-survival-b-for-patients-with.png)
Survival curves. Progression-free survival (a) and overall survival (b)... | Download Scientific Diagram
KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma | PLOS ONE
![Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers | SpringerLink Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00280-021-04277-3/MediaObjects/280_2021_4277_Fig2_HTML.png)
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers | SpringerLink
![تويتر \ JAMA Oncology على تويتر: "Radiographic progression-free survival in PREVAIL trial of #enzalutamide vs placebo for met castration-resistant #ProstateCancer is reliable & clinically meaningful endpoint highly assoc'd w overall survival https://t ... تويتر \ JAMA Oncology على تويتر: "Radiographic progression-free survival in PREVAIL trial of #enzalutamide vs placebo for met castration-resistant #ProstateCancer is reliable & clinically meaningful endpoint highly assoc'd w overall survival https://t ...](https://pbs.twimg.com/media/DXyAR9pX4AAi2yO.jpg)
تويتر \ JAMA Oncology على تويتر: "Radiographic progression-free survival in PREVAIL trial of #enzalutamide vs placebo for met castration-resistant #ProstateCancer is reliable & clinically meaningful endpoint highly assoc'd w overall survival https://t ...
![a Progression-free survival and b overall survival according to the... | Download Scientific Diagram a Progression-free survival and b overall survival according to the... | Download Scientific Diagram](https://www.researchgate.net/publication/347080538/figure/fig1/AS:998411209814016@1615051190780/a-Progression-free-survival-and-b-overall-survival-according-to-the-best-overall-response.png)
a Progression-free survival and b overall survival according to the... | Download Scientific Diagram
![Cumulative progression-free survival (PFS) (A) and overall survival... | Download Scientific Diagram Cumulative progression-free survival (PFS) (A) and overall survival... | Download Scientific Diagram](https://www.researchgate.net/profile/Toru-Beppu/publication/43148009/figure/fig1/AS:601692714319893@1520466130959/Cumulative-progression-free-survival-PFS-A-and-overall-survival-OS-B-curve-in-71.png)
Cumulative progression-free survival (PFS) (A) and overall survival... | Download Scientific Diagram
![Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/3/3/e001802/F1.large.jpg?width=800&height=600&carousel=1)
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
![Kaplan-Meier survival curves of progression-free survival and overall... | Download Scientific Diagram Kaplan-Meier survival curves of progression-free survival and overall... | Download Scientific Diagram](https://www.researchgate.net/publication/328503700/figure/fig1/AS:685619827187714@1540475913713/Kaplan-Meier-survival-curves-of-progression-free-survival-and-overall-survival-according.png)
Kaplan-Meier survival curves of progression-free survival and overall... | Download Scientific Diagram
![Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology](https://www.jcancer.org/v10/p3717/jcav10p3717g002.jpg)
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
![Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram](https://www.researchgate.net/profile/Li-Zhang-330/publication/233746224/figure/fig2/AS:601587995136000@1520441163001/Progression-free-survival-and-overall-survival-curves-for-all-patients-with-different.png)
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
![Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for. - ppt download Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for. - ppt download](https://slideplayer.com/16198544/95/images/slide_1.jpg)
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for. - ppt download
![Kaplan-Meier progression free survival and overall survival estimates... | Download Scientific Diagram Kaplan-Meier progression free survival and overall survival estimates... | Download Scientific Diagram](https://www.researchgate.net/publication/355181803/figure/fig3/AS:1077968935878663@1634019230093/Kaplan-Meier-progression-free-survival-and-overall-survival-estimates-for-MDA-vs_Q640.jpg)
Kaplan-Meier progression free survival and overall survival estimates... | Download Scientific Diagram
![Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11060-017-2619-1/MediaObjects/11060_2017_2619_Fig1_HTML.gif)
Estimating progression-free survival in patients with glioblastoma using routinely collected data | SpringerLink
![Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine | Scientific Reports Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-018-37633-0/MediaObjects/41598_2018_37633_Fig1_HTML.png)
Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine | Scientific Reports
![Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - Journal of Thoracic Oncology Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/49cd6e8f-4319-457e-af00-4dbbab967dfb/gr1.jpg)